Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) disorders. After a dramatic run from a 52-week low of $37.19 to a high of $392.70, shares have pulled back to roughly $353, making the round $500 mark a natural next milestone. The $500 stock price target has appeared repeatedly in analyst commentary — including initiation and price-target reports from firms such as Wolfe Research and Truist — giving the question real grounding in public market discussion rather than being an arbitrary figure.
PRAX carries a market capitalization of about $9.9 billion despite generating only minimal revenue, with the company reporting a net loss of $2.87 per share in its most recent quarter. The business is still transitioning from clinical-stage to commercial-stage, and its near-term value hinges almost entirely on regulatory catalysts rather than current earnings. The stock's elevated beta, reported around 2.7, underscores its high volatility and sensitivity to trial and FDA news.
The central pillar of the bullish case is ulixacaltamide, Praxis's lead candidate for essential tremor. The FDA has assigned the drug a PDUFA target action date of January 29, 2027, and it has already received Breakthrough Therapy Designation following positive Phase 3 data. Essential tremor affects millions of patients in the U.S. with no well-established FDA-approved therapy, and several analysts project multibillion-dollar peak sales potential for the first approved treatment in the category.
A second catalyst is relutrigine for SCN2A/SCN8A developmental and epileptic encephalopathies, a rare-epilepsy program that was granted priority review, with its PDUFA date extended to December 27, 2026. The company has also reported that it held roughly $1.4 billion in cash and investments as of March 2026, a balance expected to fund operations into 2028 — reducing near-term dilution risk as it builds out commercial infrastructure.
The principal obstacle is execution risk. Praxis's vormatrigine program for focal-onset seizures missed its primary endpoint in the Phase 2/3 POWER1 study and paused enrollment in POWER2, prompting a wave of price-target cuts. That setback illustrates how quickly sentiment can shift when a high-expectation asset disappoints. Additionally, because the company is pre-revenue and unprofitable, its valuation is not anchored by earnings — leaving the share price vulnerable to binary clinical outcomes and to any delay or negative FDA decision.
Despite the mixed pipeline news, the Street remains broadly constructive. The consensus rating is a "Strong Buy," with an average one-year price target near $639 and a median in the $480–$550 range, depending on the data provider. Targets span a wide band — from bearish estimates near $162 up to $1,201 from the most optimistic firm. Crucially for the $500 question, the average and median targets both sit at or above $500, indicating that most analysts already price in substantial upside beyond that threshold.
From a technical-analysis standpoint, the prior 52-week high near $392.70 is the first major resistance level the stock would need to reclaim before $500 becomes realistic. Beyond that, $400 is a psychological barrier, with $500 the next round-number objective. On the downside, support appears in the $300–$335 area, reinforced by the 50-day and 200-day moving averages. A sustained move above the $392.70 high, ideally on rising conviction, would be a key confirmation that the longer-term uptrend remains intact.
For investors tracking fast-moving names like PRAX, Tickeron's AI Daily Buy/Sell Signals offer an automated way to monitor shifting conditions. The product uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis. Traders can use these signals to surface new opportunities, keep tabs on existing positions, and identify changing market trends more efficiently. For those watching whether PRAX can build toward higher levels, the tool provides a useful, data-driven complement to traditional research.
A move to $500 for PRAX is ambitious but not implausible. It would require the stock to reclaim its prior high near $392.70, break through the $400 psychological level, and then extend roughly another 25% — a path that depends heavily on successful FDA outcomes for ulixacaltamide and relutrigine. The strong cash balance, Breakthrough Therapy Designation, and analyst targets above $500 all support the possibility. However, the vormatrigine setback and the company's pre-revenue, high-beta profile mean the downside risks are equally real. Investors should monitor upcoming PDUFA dates, commercial-launch progress, and any further pipeline readouts before drawing conclusions about whether $500 is achievable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | -0.94% | ||
| BEAM - PRAX | 40% Loosely correlated | +0.68% | ||
| ANRO - PRAX | 38% Loosely correlated | -2.34% | ||
| BHVN - PRAX | 37% Loosely correlated | -1.07% | ||
| RAPP - PRAX | 35% Loosely correlated | -3.95% | ||
| VERU - PRAX | 35% Loosely correlated | -0.38% | ||
More | ||||